Adaptive Biotechnologies Corp ADPT

Latest FY: 2025 Healthcare Diagnostics & Research
Market Price $24.57
Market Cap $3.93B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑54.8% YoY
$276.98M
3-Yr CAGR: 14.3%
Net Income ↓-140.8% YoY
-$42.00K
Net Margin: -0.0%
Free Cash Flow ↑50.5% YoY
-$48.95M
FCF Yield: -1.24%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity Efficiency
-0.0%
ROA: -0.0%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (ADPT)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2017 $38.4M $22.8M $-34.9M $-37.3M
FY 2018 $55.7M +44.8% $36.0M $-46.4M $-32.3M $-38.6M -3.5%
FY 2019 $85.1M +52.8% $62.8M $-68.6M -47.7% $205.4M $194.2M +603.4%
FY 2020 $98.4M +15.6% $75.9M $-146.2M -113.1% $-149.7M $-168.5M -186.8%
FY 2021 $154.3M +56.9% $105.0M $0.0M +100.0% $-192.7M $-254.5M -51.0%
FY 2022 $185.3M +20.1% $127.4M $0.2M +831.6% $-183.9M $-200.3M +21.3%
FY 2023 $170.3M -8.1% $94.7M $0.1M -69.5% $-156.3M $-167.0M +16.6%
FY 2024 $179.0M +5.1% $106.9M $0.1M +90.7% $-95.2M $-98.9M +40.8%
FY 2025 $277.0M +54.8% $205.6M $-0.0M -140.8% $-46.0M $-48.9M +50.5%
$

Valuation

Market Price $24.57
Market Cap $3.93B
Enterprise Value $3.86B
P/E Ratio N/A
P/B Ratio 17.48
FCF Yield -1.24%
Dividend Yield N/A
Shares Outstanding 160,044,400
%

Profitability & Margins

Gross Margin 74.24%
Operating Margin -0.02%
Net Margin -0.02%
Return on Equity (ROE) -0.02%
Return on Assets (ROA) -0.01%
Asset Turnover 0.54x
Revenue 3-Yr CAGR 14.34%
🛡️

Financial Health & Liquidity

Current Ratio 0.14
Cash Ratio 0.78
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents $70.50M
Total Debt N/A
Book Value / Share $1.41
💧

Cash Flow Efficiency

Operating Cash Flow -$45.99M
Capital Expenditures (CapEx) $2.96M
Free Cash Flow -$48.95M
OCF / Revenue -16.60%
FCF / Revenue -17.67%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) N/A
EPS (Basic) N/A
Dividends / Share N/A
Book Value / Share $1.41
EPS YoY Growth N/A
🏛️

Balance Sheet (FY 2025)

Total Assets $512.74M
Total Liabilities $287.74M
Stockholders' Equity $225.00M
Current Assets $13.02M
Current Liabilities $89.92M